

References

1. Di Pietro, M.L., et al., *Placebo-controlled trials in pediatrics and the child's best interest*. Ital J Pediatr, 2015. **41**: p. 11.
2. *Kinderformularium*. 2016 [1 August 2016]; Available from: <https://www.kinderformularium.nl/>.
3. Polanczyk, G., et al., *The worldwide prevalence of ADHD: a systematic review and metaregression analysis*. Am J Psychiatry, 2007. **164**(6): p. 942-8.
4. Jackson, J.W., *The cardiovascular safety of methylphenidate*. BMJ, 2016. **353**: p. i2874.
5. Nissen, S.E., *ADHD drugs and cardiovascular risk*. N Engl J Med, 2006. **354**(14): p. 1445-8.
6. *Flinke stijging volwassen gebruikers methylfenidaat*. 2014 [26-02-2019]; Available from: <https://www.sfk.nl/publicaties/PW/2014/flinke-stijging-volwassen-gebruikers-methylfenidaat>.
7. *Sterke daling aantal jonge gebruikers methylfenidaat*. 2019 [21-11-2019]; Available from: <https://www.sfk.nl/publicaties/PW/2019/sterkere-daling-aantal-jonge-gebruikers-methylfenidaat>.
8. *NHG-Standaard ADHD bij kinderen*. 2018 [2 October 2018]; Available from: <https://www.nhg.org/standaarden/volledig/nhg-standaard-adhd-bij-kinderen>.
9. Bachmann, C.J., A. Philipsen, and F. Hoffmann, *ADHD in Germany: Trends in Diagnosis and Pharmacotherapy*. Dtsch Arztebl Int, 2017. **114**(9): p. 141-148.
10. Mowlem, F., et al., *Do different factors influence whether girls versus boys meet ADHD diagnostic criteria? Sex differences among children with high ADHD symptoms*. Psychiatry Res, 2019. **272**: p. 765-773.
11. Bax, A.C., et al., *The Association Between Race/Ethnicity and Socioeconomic Factors and the Diagnosis and Treatment of Children with Attention-Deficit Hyperactivity Disorder*. J Dev Behav Pediatr, 2019. **40**(2): p. 81-91.
12. Marken, P.A. and J.S. Munro, *Selecting a Selective Serotonin Reuptake Inhibitor: Clinically Important Distinguishing Features*. Prim Care Companion J Clin Psychiatry, 2000. **2**(6): p. 205-210.
13. Kondro, W., *FDA urges "black box" warning on pediatric antidepressants*. CMAJ, 2004. **171**(8): p. 837-8.
14. Mullen, S., *Major depressive disorder in children and adolescents*. Ment Health Clin, 2018. **8**(6): p. 275-283.
15. Coupland, C., et al., *Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database*. BMJ, 2015. **350**: p. h517.
16. Nischal, A., et al., *Suicide and antidepressants: what current evidence indicates*. Mens Sana Monogr, 2012. **10**(1): p. 33-44.
17. Kooijman, M.N., et al., *The Generation R Study: design and cohort update 2017*. Eur J Epidemiol, 2016. **31**(12): p. 1243-1264.
18. *Foundation for Pharmaceutical Statistics*. 2019 [cited 2019; Available from: <https://www.sfk.nl/english/foundation-for-pharmaceutical-statistics>].
19. Methodology, W.C.C.f.D.S., *Guidelines for ATC Classification and DDD Assignment 2016*. Oslo, 2016.
20. Vlug, A.E., et al., *Postmarketing surveillance based on electronic patient records: the IPCI project*. Methods Inf Med, 1999. **38**(4-5): p. 339-44.
21. *ADHD-medicatie voor volwassenen goedgekeurd*. 2017 [19-12-2017 01-02-2018]; Available from: <https://www.cbg-meb.nl/actueel/nieuws/2017/12/19/adhd-medicatie-voor-volwassenen-goedgekeurd>.

22. Bakker, M.K., et al., *Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands*. BJOG, 2006. **113**(5): p. 559-68.
23. Mitchell, A.A., et al., *Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008*. Am J Obstet Gynecol, 2011. **205**(1): p. 51 e1-8.
24. Amundsen, S., et al., *Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women*. Eur J Clin Pharmacol, 2016.
25. De Ocampo, M.P., et al., *Risk of gestational hypertension and preeclampsia in women who discontinued or continued antidepressant medication use during pregnancy*. Arch Womens Ment Health, 2016.
26. Chambers, C.D., et al., *Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn*. N Engl J Med, 2006. **354**(6): p. 579-87.
27. van de Mortel, T.F., *Faking it: social desirability response bias in self-report research*. Australian Journal of Advanced Nursing, 2008. **25**(4): p. 40-48.
28. West, S.L., et al., *Recall accuracy for prescription medications: self-report compared with database information*. Am J Epidemiol, 1995. **142**(10): p. 1103-12.
29. Olesen, C., et al., *Do pregnant women report use of dispensed medications?* Epidemiology, 2001. **12**(5): p. 497-501.
30. Lagan, B.M., M. Sinclair, and W.G. Kernohan, *Internet use in pregnancy informs women's decision making: a web-based survey*. Birth, 2010. **37**(2): p. 106-15.
31. Laz, T.H. and A.B. Berenson, *Racial and ethnic disparities in internet use for seeking health information among young women*. J Health Commun, 2013. **18**(2): p. 250-60.
32. Hunt, S.M. and R. Bhopal, *Self report in clinical and epidemiological studies with non-English speakers: the challenge of language and culture*. J Epidemiol Community Health, 2004. **58**(7): p. 618-22.
33. West, S.L., et al., *Demographics, health behaviors, and past drug use as predictors of recall accuracy for previous prescription medication use*. J Clin Epidemiol, 1997. **50**(8): p. 975-80.
34. Short, M.E., et al., *How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data*. J Occup Environ Med, 2009. **51**(7): p. 786-96.
35. Reijneveld, S.A. and K. Stronks, *The validity of self-reported use of health care across socioeconomic strata: a comparison of survey and registration data*. Int J Epidemiol, 2001. **30**(6): p. 1407-14.
36. Kwon, A., et al., *Antidepressant use: concordance between self-report and claims records*. Med Care, 2003. **41**(3): p. 368-74.
37. Pisa, F.E., et al., *Medication use during pregnancy, gestational age and date of delivery: agreement between maternal self-reports and health database information in a cohort*. BMC Pregnancy Childbirth, 2015. **15**: p. 310.
38. Richardson, K., et al., *Agreement between patient interview data on prescription medication use and pharmacy records in those aged older than 50 years varied by therapeutic group and reporting of indicated health conditions*. J Clin Epidemiol, 2013. **66**(11): p. 1308-16.
39. Uiters, E., et al., *Ethnic minorities and prescription medication; concordance between self-reports and medical records*. BMC Health Serv Res, 2006. **6**: p. 115.

40. Jaddoe, V.W., et al., *The Generation R Study: Design and cohort profile*. Eur J Epidemiol, 2006. **21**(6): p. 475-84.
41. Radojic, M.R., et al., *Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: A population-based cohort study*. Neurotoxicol Teratol, 2017.
42. El Marroun, H., et al., *Prenatal exposure to selective serotonin reuptake inhibitors and non-verbal cognitive functioning in childhood*. J Psychopharmacol, 2017. **31**(3): p. 346-355.
43. El Marroun, H., et al., *Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children*. Br J Psychiatry, 2014. **205**(2): p. 95-102.
44. Elfrink, M.E., et al., *Is maternal use of medicines during pregnancy associated with deciduous molar hypomineralisation in the offspring? A prospective, population-based study*. Drug Saf, 2013. **36**(8): p. 627-33.
45. El Marroun, H., et al., *Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes*. Arch Gen Psychiatry, 2012. **69**(7): p. 706-14.
46. Statistics Netherlands. *Migrants in the Netherlands (Allochtonen in Nederland), Voorburg/Heerlen*. 2004; Available from: <http://www.cbs.nl>.
47. Walter, S.D., *Hoehler's adjusted kappa is equivalent to Yule's Y*. J Clin Epidemiol, 2001. **54**(10): p. 1072-3.
48. Viera, A.J. and J.M. Garrett, *Understanding interobserver agreement: the kappa statistic*. Fam Med, 2005. **37**(5): p. 360-3.
49. Monster, T.B., et al., *Pharmacy data in epidemiological studies: an easy to obtain and reliable tool*. Pharmacoepidemiol Drug Saf, 2002. **11**(5): p. 379-84.
50. Lau, H.S., et al., *Validation of pharmacy records in drug exposure assessment*. J Clin Epidemiol, 1997. **50**(5): p. 619-25.
51. Heerdink, E.R., et al., *Information on drug use in the elderly: a comparison of pharmacy, general-practitioner and patient data*. Pharm World Sci, 1995. **17**(1): p. 20-4.
52. Sarangarm, P., et al., *Agreement between self-report and prescription data in medical records for pregnant women*. Birth Defects Res A Clin Mol Teratol, 2012. **94**(3): p. 153-61.
53. Caskie, G.I. and S.L. Willis, *Congruence of self-reported medications with pharmacy prescription records in low-income older adults*. Gerontologist, 2004. **44**(2): p. 176-85.
54. Bryant, H.E., N. Visser, and E.J. Love, *Records, recall loss, and recall bias in pregnancy: a comparison of interview and medical records data of pregnant and postnatal women*. Am J Public Health, 1989. **79**(1): p. 78-80.
55. Reijneveld, S.A., *The cross-cultural validity of self-reported use of health care: a comparison of survey and registration data*. J Clin Epidemiol, 2000. **53**(3): p. 267-72.
56. Wells, K., et al., *Race-ethnic differences in factors associated with inhaled steroid adherence among adults with asthma*. Am J Respir Crit Care Med, 2008. **178**(12): p. 1194-201.
57. Holmes, H.M., et al., *Ethnic disparities in adherence to antihypertensive medications of medicare part D beneficiaries*. J Am Geriatr Soc, 2012. **60**(7): p. 1298-303.

58. Chong, E., et al., *Prescribing patterns and adherence to medication among South-Asian, Chinese and white people with type 2 diabetes mellitus: a population-based cohort study*. *Diabet Med*, 2014. **31**(12): p. 1586-93.
59. Lau, H.S., et al., *The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards*. *Br J Clin Pharmacol*, 2000. **49**(6): p. 597-603.
60. Zaki, N.M. and A.A. Albarraq, *Use, attitudes and knowledge of medications among pregnant women: A Saudi study*. *Saudi Pharm J*, 2014. **22**(5): p. 419-28.
61. Radin, R.G., A.A. Mitchell, and M.M. Werler, *Predictors of recall certainty of dates of analgesic medication use in pregnancy*. *Pharmacoepidemiol Drug Saf*, 2013. **22**(1): p. 25-32.
62. Reijneveld, S.A., *Reported health, lifestyles, and use of health care of first generation immigrants in The Netherlands: do socioeconomic factors explain their adverse position?* *J Epidemiol Community Health*, 1998. **52**(5): p. 298-304.
63. Impicciatore, P., et al., *Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies*. *Br J Clin Pharmacol*, 2001. **52**(1): p. 77-83.
64. *Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 3)*. 2014, European Medicines Agency. p. 14.
65. Starke, P.R., J. Weaver, and B.A. Chowdhury, *Boxed warning added to promethazine labeling for pediatric use*. *N Engl J Med*, 2005. **352**(25): p. 2653.
66. Lenk, C. and G. Duttge, *Ethical and legal framework and regulation for off-label use: European perspective*. *Ther Clin Risk Manag*, 2014. **10**: p. 537-46.
67. Aschenbrenner, D.S., *Codeine and Tramadol Contraindicated for Pediatric Use*. *Am J Nurs*, 2017. **117**(8): p. 23.
68. Bensouda-Grimaldi, L., et al., *Prescription of drugs contraindicated in children: a national community survey*. *Eur J Clin Pharmacol*, 2007. **63**(1): p. 99-101.
69. Guedon-Moreau, L., et al., *Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999*. *Eur J Clin Pharmacol*, 2004. **59**(12): p. 899-904.
70. Horen, B., J.L. Montastruc, and M. Lapeyre-Mestre, *Adverse drug reactions and off-label drug use in paediatric outpatients*. *Br J Clin Pharmacol*, 2002. **54**(6): p. 665-70.
71. Tsai, H.H., et al., *Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review*. *Int J Clin Pract*, 2012. **66**(11): p. 1056-78.
72. Teichert, M., et al., *Prevalence of inappropriate prescribing of inhaled corticosteroids for respiratory tract infections in the Netherlands: a retrospective cohort study*. *NPJ Prim Care Respir Med*, 2014. **24**: p. 14086.
73. Putignano, D., et al., *Differences in drug use between men and women: an Italian cross sectional study*. *BMC Womens Health*, 2017. **17**(1): p. 73.
74. Verbrugge, L.M., *How physicians treat mentally distressed men and women*. *Soc Sci Med*, 1984. **18**(1): p. 1-9.
75. Verbrugge, L.M. and R.P. Steiner, *Prescribing drugs to men and women*. *Health Psychol*, 1985. **4**(1): p. 79-98.

76. Regitz-Zagrosek, V., *Sex and gender differences in health. Science & Society Series on Sex and Science*. EMBO Rep, 2012. **13**(7): p. 596-603.
77. Taylor, P.N. and J.S. Davies, *A review of the growing risk of vitamin D toxicity from inappropriate practice*. Br J Clin Pharmacol, 2018.
78. Weinstein, R.B., et al., *Prevalence of Chronic Metoclopramide Use and Associated Diagnoses in the US Pediatric Population*. Paediatr Drugs, 2015. **17**(4): p. 331-7.
79. Gaillard, T., et al., *The end of a dogma: the safety of doxycycline use in young children for malaria treatment*. Malar J, 2017. **16**(1): p. 148.
80. Donovan, B.J., et al., *Treatment of tick-borne diseases*. Ann Pharmacother, 2002. **36**(10): p. 1590-7.
81. Todd, S.R., et al., *No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever*. J Pediatr, 2015. **166**(5): p. 1246-51.
82. Volovitz, B., et al., *Absence of tooth staining with doxycycline treatment in young children*. Clin Pediatr (Phila), 2007. **46**(2): p. 121-6.
83. Smith, M., *Hyperactive Around the World? The History of ADHD in Global Perspective*. Soc Hist Med, 2017. **30**(4): p. 767-787.
84. Cortese, S., et al., *Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis*. Lancet Psychiatry, 2018. **5**(9): p. 727-738.
85. Dunlop, A.J. and L.K. Newman, *ADHD and psychostimulants - overdiagnosis and overprescription*. Med J Aust, 2016. **204**(4): p. 139.
86. Miller, A.R., D. Kohen, and C. Johnston, *Child characteristics and receipt of stimulant medications: a population-based study*. Ambul Pediatr, 2008. **8**(3): p. 175-81.
87. Rashid, M.A., S. Lovick, and N.R. Llanwarne, *Medication-taking experiences in attention deficit hyperactivity disorder: a systematic review*. Fam Pract, 2018. **35**(2): p. 142-150.
88. Russell, A.E., T. Ford, and G. Russell, *Barriers and predictors of medication use for childhood ADHD: findings from a UK population-representative cohort*. Soc Psychiatry Psychiatr Epidemiol, 2019.
89. Miller, A.R., et al., *Prescription of methylphenidate to children and youth, 1990-1996*. CMAJ, 2001. **165**(11): p. 1489-94.
90. Froehlich, T.E., et al., *Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children*. Arch Pediatr Adolesc Med, 2007. **161**(9): p. 857-64.
91. Hoagwood, K., et al., *Medication management of stimulants in pediatric practice settings: a national perspective*. J Dev Behav Pediatr, 2000. **21**(5): p. 322-31.
92. McDonald, D.C. and S.K. Jalbert, *Geographic variation and disparity in stimulant treatment of adults and children in the United States in 2008*. Psychiatr Serv, 2013. **64**(11): p. 1079-86.
93. Courtabessis, E., et al., *Clinical factors associated with decision to recommend methylphenidate treatment for children with ADHD in France*. Eur Child Adolesc Psychiatry, 2018. **27**(3): p. 367-376.
94. guideline, N. *Attention deficit hyperactivity disorder: diagnosis and management*. 2018 12-07-2019]; Available from: <https://www.nice.org.uk/guidance/ng87/resources/attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933>.
95. Bussing, R., et al., *ADHD knowledge, perceptions, and information sources: perspectives from a community sample of adolescents and their parents*. J Adolesc Health, 2012. **51**(6): p. 593-600.

96. Javalkar, K., et al., *Predictors of Caregiver Burden among Mothers of Children with Chronic Conditions*. Children (Basel), 2017. **4**(5).
97. Morgan, P.L., et al., *Racial/ethnic disparities in ADHD diagnosis by kindergarten entry*. J Child Psychol Psychiatry, 2014. **55**(8): p. 905-13.
98. Golmirzaei, J., et al., *Evaluation of attention-deficit hyperactivity disorder risk factors*. Int J Pediatr, 2013. **2013**: p. 953103.
99. Gustafsson, P. and K. Kallen, *Perinatal, maternal, and fetal characteristics of children diagnosed with attention-deficit-hyperactivity disorder: results from a population-based study utilizing the Swedish Medical Birth Register*. Dev Med Child Neurol, 2011. **53**(3): p. 263-8.
100. Jablonska, B., et al., *Neighborhood Socioeconomic Characteristics and Utilization of ADHD Medication in Schoolchildren: A Population Multilevel Study in Stockholm County*. J Atten Disord, 2016.
101. Morgan, P.L., et al., *Racial and ethnic disparities in ADHD diagnosis from kindergarten to eighth grade*. Pediatrics, 2013. **132**(1): p. 85-93.
102. WCCfDS, M., *Guidelines for ATC Classification and DDD Assignment 2016*. Oslo, 2016, Methodology WCCfDS.
103. Chen, W.J., et al., *Diagnostic accuracy of the Child Behavior Checklist scales for attention-deficit hyperactivity disorder: a receiver-operating characteristic analysis*. J Consult Clin Psychol, 1994. **62**(5): p. 1017-1025.
104. Kim, J.W., et al., *The child behavior checklist together with the ADHD rating scale can diagnose ADHD in Korean community-based samples*. Can J Psychiatry, 2005. **50**(12): p. 802-5.
105. *Migrants in the Netherlands (Allochtonen in Nederland) 2004* 04 June 2019]; Available from: <http://www.cbs.nl>.
106. Schwenke, E., et al., *Predicting attention deficit hyperactivity disorder using pregnancy and birth characteristics*. Arch Gynecol Obstet, 2018. **298**(5): p. 889-895.
107. Cramer, A., et al., *The Brief Symptom Inventory and the Outcome Questionnaire-45 in the Assessment of the Outcome Quality of Mental Health Interventions*. Psychiatry J, 2016. **2016**: p. 7830785.
108. Derogatis, L.R. and N. Melisaratos, *The Brief Symptom Inventory: an introductory report*. Psychol Med, 1983. **13**(3): p. 595-605.
109. Sujan, A.C., et al., *Annual Research Review: Maternal antidepressant use during pregnancy and offspring neurodevelopmental problems - a critical review and recommendations for future research*. J Child Psychol Psychiatry, 2018.
110. Stricker, B.H. and T. Stijnen, *Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies*. Eur J Epidemiol, 2010. **25**(4): p. 245-51.
111. van den Ban, E.F., et al., *Differences in ADHD medication usage patterns in children and adolescents from different cultural backgrounds in the Netherlands*. Soc Psychiatry Psychiatr Epidemiol, 2015. **50**(7): p. 1153-62.
112. Quinn, P.O. and M. Madhoo, *A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis*. Prim Care Companion CNS Disord, 2014. **16**(3).
113. Novik, T.S., et al., *Influence of gender on attention-deficit/hyperactivity disorder in Europe--ADORE*. Eur Child Adolesc Psychiatry, 2006. **15 Suppl 1**: p. 115-24.

114. S.L. Soffer, J.A.M., T.J. Power, *Understanding Girls with Attention-Deficit/Hyperactivity Disorder (ADHD): Applying Research to Clinical Practice*. International Journal of Behavioral Consultation and Therapy, 2008. **4**(1): p. 14-29.
115. Quinn, P. and S. Wigal, *Perceptions of girls and ADHD: results from a national survey*. MedGenMed, 2004. **6**(2): p. 2.
116. Brinkman, W.B., et al., *Physicians' shared decision-making behaviors in attention-deficit/hyperactivity disorder care*. Arch Pediatr Adolesc Med, 2011. **165**(11): p. 1013-9.
117. McQuaid, E.L., *Barriers to medication adherence in asthma: The importance of culture and context*. Ann Allergy Asthma Immunol, 2018. **121**(1): p. 37-42.
118. Brinkman, W.B., et al., *Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder*. Pediatrics, 2009. **124**(2): p. 580-9.
119. Flaskerud, J.H., *Ethnicity, culture, and neuropsychiatry*. Issues Ment Health Nurs, 2000. **21**(1): p. 5-29.
120. Coker, T.R., et al., *Racial and Ethnic Disparities in ADHD Diagnosis and Treatment*. Pediatrics, 2016. **138**(3).
121. Stevens, J., J.S. Harman, and K.J. Kelleher, *Race/ethnicity and insurance status as factors associated with ADHD treatment patterns*. J Child Adolesc Psychopharmacol, 2005. **15**(1): p. 88-96.
122. Cummings, J.R., et al., *Racial and Ethnic Differences in ADHD Treatment Quality Among Medicaid-Enrolled Youth*. Pediatrics, 2017. **139**(6).
123. Alegria, M., et al., *Disparity in depression treatment among racial and ethnic minority populations in the United States*. Psychiatr Serv, 2008. **59**(11): p. 1264-72.
124. Buitelaar, N., Yildirim, V., *Onderbehandeling van ADHD bij allochtonen: kinderen en volwassenen*. ADHD Actueel, 2006. **4**: p. 1-12.
125. Dosreis, S., et al., *Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder*. J Dev Behav Pediatr, 2003. **24**(3): p. 155-62.
126. Paidipati, C.P., et al., *Parent and Family Processes Related to ADHD Management in Ethnically Diverse Youth*. J Am Psychiatr Nurses Assoc, 2017. **23**(2): p. 90-112.
127. Thapar, A., et al., *Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring*. Am J Psychiatry, 2003. **160**(11): p. 1985-9.
128. Barner, J.C., S. Khoza, and A. Oladapo, *ADHD medication use, adherence, persistence and cost among Texas Medicaid children*. Curr Med Res Opin, 2011. **27** Suppl 2: p. 13-22.
129. Adler, L.D. and A.A. Nierenberg, *Review of medication adherence in children and adults with ADHD*. Postgrad Med, 2010. **122**(1): p. 184-91.
130. Skoglund, C., et al., *Factors Associated With Adherence to Methylphenidate Treatment in Adult Patients With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders*. J Clin Psychopharmacol, 2016. **36**(3): p. 222-8.
131. Semerci, B., et al., *Factors predicting treatment adherence in patients with adult attention-deficit/hyperactivity disorder: a preliminary study*. Atten Defic Hyperact Disord, 2016. **8**(3): p. 139-47.
132. Sobanski, E., et al., *Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate*. Eur Psychiatry, 2014. **29**(5): p. 324-30.

133. Nagae, M., et al., *Factors affecting medication adherence in children receiving outpatient pharmacotherapy and parental adherence*. J Child Adolesc Psychiatr Nurs, 2015. **28**(2): p. 109-17.
134. Thiruchelvam, D., A. Charach, and R.J. Schachar, *Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD*. J Am Acad Child Adolesc Psychiatry, 2001. **40**(8): p. 922-8.
135. Hugtenburg, J.G., I. Witte, and E.R. Heerdink, *Determinants of compliance with methylphenidate therapy in children*. Acta Paediatr, 2006. **95**(12): p. 1674-6.
136. Gau, S.S., et al., *Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures*. J Child Adolesc Psychopharmacol, 2006. **16**(3): p. 286-97.
137. Gajria, K., et al., *Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review*. Neuropsychiatr Dis Treat, 2014. **10**: p. 1543-69.
138. Miller, A.R., C.E. Lalonde, and K.M. McGrail, *Children's persistence with methylphenidate therapy: a population-based study*. Can J Psychiatry, 2004. **49**(11): p. 761-8.
139. Wang, L.J., et al., *Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan*. PLoS One, 2016. **11**(8): p. e0161061.
140. Rolnick, S.J., et al., *Patient characteristics associated with medication adherence*. Clin Med Res, 2013. **11**(2): p. 54-65.
141. Conners, C.K., et al., *The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity*. J Abnorm Child Psychol, 1998. **26**(4): p. 257-68.
142. Roman, G.C., et al., *Association of gestational maternal hypothyroxinemia and increased autism risk*. Ann Neurol, 2013. **74**(5): p. 733-42.
143. Safavi, P., M. Saberzadeh, and A.M. Tehrani, *Factors Associated with Treatment Adherence in Children with Attention Deficit Hyperactivity Disorder*. Indian J Psychol Med, 2019. **41**(3): p. 252-257.
144. Buuren, S.v., *Flexible Imputation of Missing Data*. Second Edition ed. Chapman & Hall/CRC Interdisciplinary Statistics 2018: Taylor & Francis Ltd. 416.
145. Gayer, D. and L. Ganong, *Family structure and mothers' caregiving of children with cystic fibrosis*. J Fam Nurs, 2006. **12**(4): p. 390-412.
146. Coletti, D.J., et al., *Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorder*. J Child Adolesc Psychopharmacol, 2012. **22**(3): p. 226-37.
147. Frank, E., et al., *Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis*. J Clin Psychiatry, 2015. **76**(11): p. e1459-68.
148. Setlik, J., G.R. Bond, and M. Ho, *Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications*. Pediatrics, 2009. **124**(3): p. 875-80.
149. Palli, S.R., et al., *Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder*. J Child Adolesc Psychopharmacol, 2012. **22**(2): p. 139-48.
150. Punja, S., et al., *Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy*. BMJ Open, 2013. **3**(3).
151. Ehrhardt, C., et al., *Methylphenidate: Gender trends in adult and pediatric populations over a 7year period*. Therapie, 2017. **72**(6): p. 635-641.

152. *Richtlijn ADHD bij volwassenen, in Fase I - Diagnostiek en medicamenteuze behandeling 2015*, Nederlandse Vereniging voor Psychiatrie. p. 72-73.
153. Biederman, J., E. Mick, and S.V. Faraone, *Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type*. Am J Psychiatry, 2000. **157**(5): p. 816-8.
154. Hurtig, T., et al., *ADHD symptoms and subtypes: relationship between childhood and adolescent symptoms*. J Am Acad Child Adolesc Psychiatry, 2007. **46**(12): p. 1605-13.
155. Hauck, T.S., et al., *ADHD Treatment in Primary Care: Demographic Factors, Medication Trends, and Treatment Predictors*. Can J Psychiatry, 2017. **62**(6): p. 393-402.
156. McCarthy, S., et al., *Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence*. BMC Psychiatry, 2012. **12**: p. 219.
157. van der Lei, J., et al., *The introduction of computer-based patient records in The Netherlands*. Ann Intern Med, 1993. **119**(10): p. 1036-41.
158. Schelleman, H., et al., *Methylphenidate and risk of serious cardiovascular events in adults*. Am J Psychiatry, 2012. **169**(2): p. 178-85.
159. Vasan, R.S., et al., *Impact of high-normal blood pressure on the risk of cardiovascular disease*. N Engl J Med, 2001. **345**(18): p. 1291-7.
160. Cooney, M.T., et al., *Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women*. Am Heart J, 2010. **159**(4): p. 612-619 e3.
161. Perret-Guillaume, C., L. Joly, and A. Benetos, *Heart rate as a risk factor for cardiovascular disease*. Prog Cardiovasc Dis, 2009. **52**(1): p. 6-10.
162. Liang, E.F., et al., *The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression*. Int J Environ Res Public Health, 2018. **15**(8).
163. SFK. *Toename in gebruik van methylfenidaat lijkt voorbij*. 21 September 2017 25-11-2018]; Available from: <https://www.sfk.nl/publicaties/PW/2017/Toename%20methylfenidaat%20voorbij>.
164. SFK. *Flinke stijging volwassen gebruikers methylfenidaat*. 30 October 2014 25-11-2018]; Available from: <https://www.sfk.nl/publicaties/PW/2014/flinke-stijging-volwassen-gebruikers-methylfenidaat>.
165. *Richtlijn ADHD bij volwassenen, in Fase I - Diagnostiek en medicamenteuze behandeling 2015*: Nederlandse Vereniging voor Psychiatrie.
166. McCarthy, S., et al., *Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults*. Br J Psychiatry, 2009. **194**(3): p. 273-7.
167. Faraone, S.V., J. Biederman, and E. Mick, *The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies*. Psychol Med, 2006. **36**(2): p. 159-65.
168. Zetterqvist, J., et al., *Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009*. Acta Psychiatr Scand, 2013. **128**(1): p. 70-7.
169. Kessler, R.C., et al., *Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication*. Biol Psychiatry, 2005. **57**(11): p. 1442-51.

170. Brinkman, W.B., J.O. Simon, and J.N. Epstein, *Reasons Why Children and Adolescents With Attention-Deficit/Hyperactivity Disorder Stop and Restart Taking Medicine*. Acad Pediatr, 2018. **18**(3): p. 273-280.
171. Pottsgard, A., et al., *Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: a Danish nationwide drug utilization study*. Basic Clin Pharmacol Toxicol, 2015. **116**(4): p. 349-53.
172. Ford-Jones, P.C., *Misdiagnosis of attention deficit hyperactivity disorder: 'Normal behaviour' and relative maturity*. Paediatr Child Health, 2015. **20**(4): p. 200-2.
173. Sperber, C.M., S.R. Samarasinghe, and G.P. Lomax, *An upper and lower bound of the Medication Possession Ratio*. Patient Prefer Adherence, 2017. **11**: p. 1469-1478.
174. Clemow, D.B., *Misuse of Methylphenidate*. Curr Top Behav Neurosci, 2017. **34**: p. 99-124.
175. Cairns, R., et al., *ADHD medication overdose and misuse: the NSW Poisons Information Centre experience, 2004-2014*. Med J Aust, 2016. **204**(4): p. 154.
176. Weibel, S., et al., *Overuse or underuse of methylphenidate in adults in France: commentary on Pauly et al. 2018*. Br J Clin Pharmacol, 2018.
177. Bjerkeli, P.J., et al., *Overuse of methylphenidate: an analysis of Swedish pharmacy dispensing data*. Clin Epidemiol, 2018. **10**: p. 1657-1665.
178. Weyandt, L.L., et al., *Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants*. Psychol Res Behav Manag, 2014. **7**: p. 223-49.
179. *Minder gebruikers in 2017 van ADHD-middel methylfenidaat*. 2018 [26-02-2019]; Available from: <https://www.sfk.nl/publicaties/PW/2018/minder-gebruikers-in-2017-van-adhd-middel-methylfenidaat>.
180. Bachmann, C.J., et al., *Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012*. Eur Neuropsychopharmacol, 2017. **27**(5): p. 484-493.
181. van den Ban, E., et al., *Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006*. J Child Adolesc Psychopharmacol, 2010. **20**(1): p. 55-61.
182. Davidovitch, M., et al., *Challenges in defining the rates of ADHD diagnosis and treatment: trends over the last decade*. BMC Pediatr, 2017. **17**(1): p. 218.
183. Goldsmith S, P.T., Kleinman A, et al, *Reducing Suicide: A National Imperative*, B.o.N.a.B.H. Committee on Pathophysiology & Prevention of Adolescent & Adult Suicide, Editor. 2002: Washington D.C.
184. Brent, D.A., *Depression and suicide in children and adolescents*. Pediatr Rev, 1993. **14**(10): p. 380-8.
185. Usala, T., et al., *Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis*. Eur Neuropsychopharmacol, 2008. **18**(1): p. 62-73.
186. Anderson, I.M., *Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability*. J Affect Disord, 2000. **58**(1): p. 19-36.
187. Martinez, C., et al., *Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study*. BMJ, 2005. **330**(7488): p. 389.

188. Hall, W.D. and J. Lucke, *How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality?* Aust N Z J Psychiatry, 2006. **40**(11-12): p. 941-50.
189. Fergusson, D., et al., *Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials.* BMJ, 2005. **330**(7488): p. 396.
190. Juurlink, D.N., et al., *The risk of suicide with selective serotonin reuptake inhibitors in the elderly.* Am J Psychiatry, 2006. **163**(5): p. 813-21.
191. Mihanovic, M., et al., *Suicidality and side effects of antidepressants and antipsychotics.* Psychiatr Danub, 2010. **22**(1): p. 79-84.
192. Isacson, G., et al., *Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995-2005.* Acta Psychiatr Scand, 2009. **120**(1): p. 37-44.
193. Arias, L.H., et al., *Trends in the consumption of antidepressants in Castilla y Leon (Spain). Association between suicide rates and antidepressant drug consumption.* Pharmacoepidemiol Drug Saf, 2010. **19**(9): p. 895-900.
194. Gibbons, R.D., et al., *Relationship between antidepressants and suicide attempts: An analysis of the veterans health administration data sets.* American Journal of Psychiatry, 2007. **164**(7): p. 1044-1049.
195. Jick, H., J.A. Kaye, and S.S. Jick, *Antidepressants and the risk of suicidal behaviors.* JAMA, 2004. **292**(3): p. 338-43.
196. Didham, R.C., et al., *Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication.* Br J Clin Pharmacol, 2005. **60**(5): p. 519-25.
197. Lamberts, H., M. Wood, and I.M. Hofmans-Okkes, *International primary care classifications: the effect of fifteen years of evolution.* Fam Pract, 1992. **9**(3): p. 330-9.
198. Teti, G.L., et al., *Systematic review of risk factors for suicide and suicide attempt among psychiatric patients in Latin America and Caribbean.* Rev Panam Salud Publica, 2014. **36**(2): p. 124-33.
199. Kragh-Sorensen, P., *Pharmacotherapy of the suicidal patient.* Acta Psychiatr Scand Suppl, 1993. **371**: p. 57-9.
200. Rihmer, Z., *Suicide risk in mood disorders.* Curr Opin Psychiatry, 2007. **20**(1): p. 17-22.
201. Wichstrom, L., *Predictors of adolescent suicide attempts: a nationally representative longitudinal study of Norwegian adolescents.* J Am Acad Child Adolesc Psychiatry, 2000. **39**(5): p. 603-10.
202. Spirito, A., et al., *Predictors of continued suicidal behavior in adolescents following a suicide attempt.* J Clin Child Adolesc Psychol, 2003. **32**(2): p. 284-9.
203. Stone, M., et al., *Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration.* BMJ, 2009. **339**: p. b2880.
204. Barbui, C., E. Esposito, and A. Cipriani, *Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies.* CMAJ, 2009. **180**(3): p. 291-7.
205. Coupland, C., et al., *Antidepressant use and risk of adverse outcomes in older people: population based cohort study.* BMJ, 2011. **343**: p. d4551.
206. Simon, G.E., et al., *Suicide risk during antidepressant treatment.* Am J Psychiatry, 2006. **163**(1): p. 41-7.
207. Richelson, E., *Pharmacology of antidepressants.* Mayo Clin Proc, 2001. **76**(5): p. 511-27.

208. Khawam, E.A., G. Laurencic, and D.A. Malone, Jr., *Side effects of antidepressants: an overview*. *Cleve Clin J Med*, 2006. **73**(4): p. 351-3, 356-61.
209. Breggin, P.R., *Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis*. *Int J Risk Saf Med.* , 2003/2004. **16**: p. 31-49.
210. Todder, D. and B.T. Baune, *Recurrence of suicidal ideation due to treatment with antidepressants in anxiety disorder: a case report*. *J Med Case Rep*, 2007. **1**: p. 166.
211. Strom, B.L. and J.L. Carson, *Use of automated databases for pharmacoepidemiology research*. *Epidemiol Rev*, 1990. **12**: p. 87-107.
212. Mandour, R.A., *Antidepressants medications and the relative risk of suicide attempt*. *Toxicol Int*, 2012. **19**(1): p. 42-6.
213. Gardarsdottir, H., et al., *Indications for antidepressant drug prescribing in general practice in the Netherlands*. *J Affect Disord*, 2007. **98**(1-2): p. 109-15.
214. Thomas, K.H., et al., *Validation of suicide and self-harm records in the Clinical Practice Research Datalink*. *Br J Clin Pharmacol*, 2013. **76**(1): p. 145-57.
215. Fiks, A.G., et al., *Contrasting parents' and pediatricians' perspectives on shared decision-making in ADHD*. *Pediatrics*, 2011. **127**(1): p. e188-96.
216. Lipstein, E.A., W.B. Brinkman, and M.T. Britto, *What is known about parents' treatment decisions? A narrative review of pediatric decision making*. *Med Decis Making*, 2012. **32**(2): p. 246-58.
217. Cormier, E., *How parents make decisions to use medication to treat their child's ADHD: a grounded theory study*. *J Am Psychiatr Nurses Assoc*, 2012. **18**(6): p. 345-56.
218. Manos, M.J., K. Giuliano, and E. Geyer, *ADHD: Overdiagnosed and overtreated, or misdiagnosed and mistreated?* *Cleve Clin J Med*, 2017. **84**(11): p. 873-880.
219. Merten, E.C., et al., *Overdiagnosis of mental disorders in children and adolescents (in developed countries)*. *Child Adolesc Psychiatry Ment Health*, 2017. **11**: p. 5.
220. Slobodin, O. and C.L. Crunelle, *Mini Review: Socio-Cultural Influences on the Link Between ADHD and SUD*. *Front Public Health*, 2019. **7**: p. 173.
221. Agnew-Blais, J.C., et al., *Evaluation of the Persistence, Remission, and Emergence of Attention-Deficit/Hyperactivity Disorder in Young Adulthood*. *JAMA Psychiatry*, 2016. **73**(7): p. 713-20.
222. Vitiello, B., *Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder*. *J Child Adolesc Psychopharmacol*, 2001. **11**(1): p. 25-34.
223. Volkow, N.D. and T.R. Insel, *What are the long-term effects of methylphenidate treatment?* *Biol Psychiatry*, 2003. **54**(12): p. 1307-9.
224. Schrantee, A., et al., *Long-term effects of stimulant exposure on cerebral blood flow response to methylphenidate and behavior in attention-deficit hyperactivity disorder*. *Brain Imaging Behav*, 2018. **12**(2): p. 402-410.
225. dos Santos Pereira, M., et al., *Long Withdrawal of Methylphenidate Induces a Differential Response of the Dopaminergic System and Increases Sensitivity to Cocaine in the Prefrontal Cortex of Spontaneously Hypertensive Rats*. *PLoS One*, 2015. **10**(10): p. e0141249.
226. Krakowski, A. and A. Ickowicz, *Stimulant Withdrawal in a Child with Autism Spectrum Disorder and ADHD - A Case Report*. *J Can Acad Child Adolesc Psychiatry*, 2018. **27**(2): p. 148-151.

227. Chung, W., et al., *Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder Among Adults and Children of Different Racial and Ethnic Groups*. JAMA Netw Open, 2019. **2**(11): p. e1914344.
228. Park, M.S., *Off-label use and designation of age group-specific contraindications for pharmacotherapy in children in Korea*. Transl Clin Pharmacol, 2014. **22**(2): p. 58-63.
229. *Paediatric Regulation*. 2020 04-01-2020]; Available from: <https://www.ema.europa.eu/en/human-regulatory/overview/paediatric-medicines/paediatric-regulation>.
230. Rocchi, F., et al., *The European paediatric legislation: benefits and perspectives*. Ital J Pediatr, 2010. **36**: p. 56.
231. Papazisis, G., et al., *Nonmedical Use of Prescription Medications Among Medical Students in Greece: Prevalence of and Motivation for Use*. Subst Use Misuse, 2018. **53**(1): p. 77-85.
232. Jain, R., et al., *Non-medical use of methylphenidate among medical students of the University of the Free State*. S Afr J Psychiatr, 2017. **23**: p. 1006.
233. Jeremy T.S., R.L.A., *Recreational stimulant use among college students*. Journal of Substance Use, 2009. **12**(2): p. 71-82.
234. Stein, M.A., M. Weiss, and L. Hlavaty, *ADHD treatments, sleep, and sleep problems: complex associations*. Neurotherapeutics, 2012. **9**(3): p. 509-17.
235. Wessely, S. and R. Kerwin, *Suicide risk and the SSRIs*. JAMA, 2004. **292**(3): p. 379-81.
236. Morales-Rios, O., et al., *Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico*. PLoS One, 2018. **13**(1): p. e0190882.
237. Song, I., S.H. Choi, and J.Y. Shin, *Trends in prescription of pregnancy-contraindicated drugs in Korea, 2007-2011*. Regul Toxicol Pharmacol, 2016. **75**: p. 35-45.
238. Chen, Y.F., et al., *Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice*. Drug Saf, 2005. **28**(1): p. 67-80.
239. Damagnez, M., et al., *[Drugs contraindicated in children: a study of drug prescriptions in ambulatory medicine in the south of France (Aude Department)] Medicaments contre-indiqués chez l'enfant: analyse des prescriptions en médecine de ville dans le département de l'Aude*. Therapie, 2005. **60**(5): p. 507-13.
240. Song, I., H.N. Shin, and J.Y. Shin, *Decrease in use of contraindicated drugs with automated alerts in children*. Pediatr Int, 2017. **59**(6): p. 720-726.